nach oben

Internal and Emergency Medicine

Erschienen in:

11.07.2020 | COVID-19 | IM - REVIEW Zur Zeit gratis

COVID-19, coagulopathy and venous thromboembolism: more questions than answers

verfasst von: Marco Marietta, Valeria Coluccio, Mario Luppi

Erschienen in: Internal and Emergency Medicine | Ausgabe 8/2020

Einloggen, um Zugang zu erhalten

Abstract

The acute respiratory illnesses caused by severe acquired respiratory syndrome corona Virus-2 (SARS-CoV-2) is a global health emergency, involving more than 8.6 million people worldwide with more than 450,000 deaths. Among the clinical manifestations of COVID-19, the disease that results from SARS-CoV-2 infection in humans, a prominent feature is a pro-thrombotic derangement of the hemostatic system, possibly representing a peculiar clinicopathologic manifestation of viral sepsis. The severity of the derangement of coagulation parameters in COVID-19 patients has been associated with a poor prognosis, and the use of low molecular weight heparin (LMWH) at doses registered for prevention of venous thromboembolism (VTE) has been endorsed by the World Health Organization and by Several Scientific societies. However, some relevant issues on the relationships between COVID-19, coagulopathy and VTE have yet to be fully elucidated. This review is particularly focused on four clinical questions: What is the incidence of VTE in COVID-19 patients? How do we frame the COVID-19 associated coagulopathy? Which role, if any, do antiphospolipid antibodies have? How do we tackle COVID-19 coagulopathy? In the complex scenario of an overwhelming pandemic, most everyday clinical decisions have to be taken without delay, although not yet supported by a sound scientific evidence. This review discusses the most recent findings of basic and clinical research about the COVID-associated coagulopathy, to foster a more thorough knowledge of the mechanisms underlying this compelling disease.

World Health Organization. Coronavirus disease (COVID-19) Situation Report–152. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200620-covid-19-sitrep-152.pdf?sfvrsn=83aff8ee_4. Accessed June 21, 2020

Huang C, Wang Y, Li X et al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395:497–506. https://doi.org/10.1016/S0140-6736(20)30183-5CrossRef

Han H, Yang L, Liu R et al (2020) Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med. https://doi.org/10.1515/cclm-2020-0188.HCrossRef

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z (2020) Clinical characteristics of 138 hospitalized patients With 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 323:1061–1069. https://doi.org/10.1001/jama.2020.1585CrossRef

Cao X (2020) COVID-19: immunopathology and its implications for therapy. Nat Rev Immunol 20(5):269–270. https://doi.org/10.1038/s41577-020-0308-3CrossRef

Moon C (2020) Fighting COVID-19 exhausts T cells. Nat Rev Immunol. https://doi.org/10.1038/s41577-020-0304-7CrossRef

Iba T, Levy JH, Levi M, Thachil J (2020) Coagulopathy in COVID-19. J Thromb Haemost. https://doi.org/10.1111/jth.14975CrossRef

Tang N, Li D, Wang X, Sun Z (2020) Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 18:844–847. https://doi.org/10.1111/jth.14768CrossRef

Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S et al (2020) Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 13:e200994. https://doi.org/10.1001/jamainternmed.2020.0994CrossRef

10.

Tang N, Bai H, Chen X, Gong J, Li D, Sun Z (2020) Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. https://doi.org/10.1111/jth.14817CrossRef

11.

WHO Interim guidance (2020) Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. Published 13 March 2020. https://apps.who.int/iris/handle/10665/331446. Accessed May 5 2020

12.

Tcachil J, Tang N, Gando S, Cattaneo M, Levi M, Clark C, Iba T (2020) ISTH interim guidance on recognition and management of coagulopathy in COVID-19. Journal Thomb Haemost. https://doi.org/10.1111/jth.14810CrossRef

13.

Marietta M, Ageno W, Artoni A, De Candia E, Gresele P, Marchetti M, Marcucci R, Tripodi A (2020) COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET). Blood Transfus. https://doi.org/10.2450/2020.0083-20CrossRef

14.

Casini A, Alberio L, Angelillo-Scherrer A, Fontana P, Gerber B, Graf L et al (2020) Working party on hemostasis of the Swiss Society of Hematology. Suggestions for thromboprophylaxis and laboratory monitoring for in-hospital patients with COVID-19. Swiss Med Wkly 150:w20247. https://doi.org/10.4414/smw.2020.20247CrossRef

15.

Zhai Z, Li C, Chen Y, Gerotziafas G, Zhang Z, Wan J et al (2020) Prevention treatment of VTE associated with COVID-19 Infection Consensus Statement Group. Prevention and treatment of venous thromboembolism associated with coronavirus disease 2019 infection: a consensus statement before guidelines. Thromb Haemost. https://doi.org/10.1055/s-0040-1710019CrossRef

16.

American Society of Hematology COVID-19 Resources. COVID-19 and VTE/Anticoagulation: frequently asked questions. https://www.hematology.org/covid-19/covid-19-and-vte-anticoagulation. Accessed 06 May 2020

17.

Barnes GD, Burnett A, Allen A, Blumenstein M, Clark NP, Cuker A et al (2020) Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum. J Thromb Thrombolysis. https://doi.org/10.1007/s11239-020-02138-zCrossRef

18.

Moores LK, Tritschler T, Brosnahan S, Carrier M, Collen JF, Doerschug K, Holley AB, Jimenez D, LeGal G, Rali P, Wells P (2020) Prevention, diagnosis and treatment of venous thromboembolism in patients with COVID-19: CHEST guideline and expert panel report. Chest S0012–3692(20):31625. https://doi.org/10.1016/j.chest.2020.05.559CrossRef

19.

Cattaneo M, Bertinato EM, Birocchi S, Brizio C, Malavolta D, Manzoni M, Muscarella G, Orlandi M (2020) Pulmonary embolism or pulmonary thrombosis in COVID-19? Is the recommendation to use high-dose heparin for thromboprophylaxis justified? Thromb Haemost. https://doi.org/10.1055/s-0040-1712097CrossRef

20.

Zhang L, Feng X, Zhang D, Jiang C, Mei H, Wang J et al (2020) Deep vein thrombosis in hospitalized patients with coronavirus Disease 2019 (COVID-19) in Wuhan, China: prevalence, risk factors, and outcome. Circulation. https://doi.org/10.1161/CIRCULATIONAHA.120.046702CrossRef

21.

Lodigiani C, Iapichino G, Carenzo L, Cecconi M, Ferrazzi P, Sebastian T, Kucher N, Studt JD, Sacco C, Alexia B, Sandri MT, Barco S, Humanitas COVID-19 Task Force (2020) Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res 191:9–14. https://doi.org/10.1016/j.thromres.2020.04.024CrossRef

22.

Middeldorp S, Coppens M, van Haaps TF, Foppen M, Vlaar AP, Müller MCA, Bouman CCS, Beenen LFM, Kootte RS, Heijmans J, Smits LP, Bonta PI, van Es N (2020) Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. https://doi.org/10.1111/jth.14888CrossRef

23.

Thomas W, Varley J, Johnston A, Symington Robinson M, Sheares K, Lavinio A, Besseret M (2020) Thrombotic complications of patients admitted to intensive care with COVID-19 at a teaching hospital in the United Kingdom. Thromb Res. https://doi.org/10.1016/j.thromres.2020.04.028CrossRef

24.

Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers D, Kant KM, Kaptein FHJ, van Paassen J, Stals MAM, Huisman MV, Endeman H (2020) Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. Thromb Res. https://doi.org/10.1016/j.thromres.2020.04.041CrossRef

25.

Poissy J, Goutay J, Caplan M, Parmentier E, Duburcq T, Lassalle F, Jeanpierre E, Rauch A, Labreuche J, Susen S, Lille ICU Haemostasis COVID-19 group (2020) Pulmonary Embolism in COVID-19 patients: awareness of an increased prevalence. Circulation. https://doi.org/10.1161/circulationaha.120.047430CrossRef

26.

Cui S, Chen S, Li X, Liu S, Wang F (2020) Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. https://doi.org/10.1111/jth.14830CrossRef

27.

Llitjos JF, Leclerc M, Chochois C, Monsallier JM, Ramakers M, Auvray M, Merouani K (2020) High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost. https://doi.org/10.1111/jth.14869CrossRef

28.

Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X et al (2020) CRICS TRIGGERSEP Group (Clinical Research in Intensive Care and Sepsis Trial Group for Global Evaluation and Research in Sepsis). High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. https://doi.org/10.1007/s00134-020-06062-xCrossRef

29.

Wichmann D, Sperhake JP, Lütgehetmann M, Steurer S, Edler C, Heinemann A et al (2020) Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study. Ann Intern Med. https://doi.org/10.7326/M20-2003CrossRef

30.

Violi F, Pastori D, Cangemi R, Pignatelli P, Loffredo L (2020) Hypercoagulation and antithrombotic treatment in coronavirus 2019: a new challenge. Thromb Haemost. https://doi.org/10.1055/s-0040-1710317CrossRef

31.

Becker RC (2020) COVID-19 update: Covid-19-associated coagulopathy. J Thromb Thrombolysis 15:1–14. https://doi.org/10.1007/s11239-020-02134-3CrossRef

32.

Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, Nigoghossian Der et al (2020) COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol. https://doi.org/10.1016/j.jacc.2020.04.031CrossRef

33.

Thachil J, Agarwal S (2020) Understanding the COVID-19 coagulopathy spectrum. Anaesthesia. https://doi.org/10.1111/anae.15141CrossRef

34.

Boccia M, Aronne L, Celia B, Mazzeo G, Ceparano M, D’Agnano V et al (2020) COVID-19 and coagulative axis: review of emerging aspects in a novel disease. Monaldi Arch Chest Dis. https://doi.org/10.4081/monaldi.2020.1300CrossRef

35.

Jackson SP, Darbousset R, Schoenwaelder SM (2019) Thromboinflammation: challenges of therapeutically targeting coagulation and other host defense mechanisms. Blood 133:906–918. https://doi.org/10.1182/blood-2018-11-882993CrossRef

36.

Iba T, Levy JH (2018) Inflammation and thrombosis: roles of neutrophils, platelets and endothelial cells and their interactions in thrombus formation during sepsis. J Thromb Haemost 16:231–241. https://doi.org/10.1111/jth.13911CrossRef

37.

Claushuis TAM, de Stoppelaar SF, Stroo I, Roelofs JJ, Ottenhoff R, van der Poll T, Van’t Veer C (2017) Thrombin contributes to protective immunity in pneumonia-derived sepsis via fibrin polymerization and platelet–neutrophil interactions. J Thromb Haemost 15:744–757. https://doi.org/10.1182/blood-2017-06-788067CrossRef

38.

Burzynski LC, Humphry M, Pyrillou K, Wiggins KA, Chan JNE, Figg N, Kitt LL et al (2019) The coagulation and immune systems are directly linked through the activation of interleukin-1α by thrombin. Immunity 50(1033–1042):e6. https://doi.org/10.1016/j.immuni.2019.03.003CrossRef

39.

Chen J, Li X, Li L et al (2019) Coagulation factors VII, IX and X are effective antibacterial proteins against drug-resistant Gram-negative bacteria. Cell Res 29:711–724. https://doi.org/10.1038/s41422-019-0202-3CrossRef

40.

Assinger A, Schrottmaier WC, Salzmann M, Rayes J (2019) Platelets in sepsis: an update on experimental models and clinical data. Front Immunol 10:1687. https://doi.org/10.3389/fimmu.2019.01687CrossRef

41.

Grover SP, Mackman N (2018) Tissue factor: an essential mediator of hemostasis and trigger of thrombosis. Arterioscler Thromb Vasc Biol 38:709–725. https://doi.org/10.1161/ATVBAHA.117.309846CrossRef

42.

Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H et al (2020) Clinical and immunologic features in severe and moderate Coronavirus Disease 2019. J Clin Invest 130:2620–2629. https://doi.org/10.1172/JCI137244CrossRef

43.

Colafrancesco S, Alessandri C, Conti F, Priori R (2020) COVID-19 gone bad: a new character in the spectrum of the hyperferritinemic syndrome? Autoimmun Rev 19:102573. https://doi.org/10.1016/j.autrev.2020.10257CrossRef

44.

Ranucci M, Ballotta A, Di Dedda U, Bayshnikova E, Dei Poli M, Resta M, Falco M, Albano G, Menicanti L (2020) The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. J Thromb Haemost. https://doi.org/10.1111/jth.14854CrossRef

45.

Panigada M, Bottino N, Tagliabue P, Grasselli G, Novembrino C, Chantarangkul V, Pesenti A, Peyvandi F, Tripodi A (2020) Hypercoagulability of COVID-19 patients in intensive care unit a report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemost. https://doi.org/10.1111/jth.14850CrossRef

46.

Spiezia L, Boscolo A, Poletto F, Cerruti L, Tiberio I, Campello E, Navalesi P, Simioni P (2020) COVID-19-related severe hypercoagulability in patients admitted to intensive care unit for acute respiratory failure. Thromb Haemost. https://doi.org/10.1055/s-0040-1710018CrossRef

47.

Han H, Yang L, Liu R et al (2020) Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med. https://doi.org/10.1515/cclm-2020-0188CrossRef

48.

Lippi G, Favaloro EJ (2020) D-dimer is associated with severity of coronavirus disease 2019: a pooled analysis. Thromb Haemost 120:876–878. https://doi.org/10.1055/s-0040-1709650CrossRef

49.

Rodelo JR, De la Rosa G, Valencia ML et al (2012) D-dimer is a significant prognostic factor in patients with suspected infection and sepsis. Am J Emerg Med 30:1991–1999. https://doi.org/10.1016/j.ajem.2012.04.033CrossRef

50.

Favaloro EJ, Thachil J (2020) Reporting of D-dimer data in COVID-19: some confusion and potential for misinformation. Clin Chem Lab Med. https://doi.org/10.1515/cclm-2020-0573CrossRef

51.

Semeraro F, Ammollo CT, Caironi P et al (2019) D-dimer corrected for thrombin and plasmin generation is a strong predictor of mortality in patients with sepsis. Blood Transfus 19:1–8. https://doi.org/10.2450/2019.0175-19CrossRef

52.

Wright FL, Vogler TO, Moore EE, Moore HB, Wohlauer MV, Urban S et al (2020) Fibrinolysis shutdown correlates to thromboembolic events in severe COVID-19 infection. Am Coll Surg. https://doi.org/10.1016/j.jamcollsurg.2020.05.007CrossRef

53.

Iba T, Levy JH, Warkentin TE, Thachil J, van der Poll T, Levi M (2019) Scientific and standardization committee on DIC, and the scientific and standardization committee on perioperative and critical care of the international society on thrombosis and haemostasis. Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation. J Thromb Haemost 17(11):1989–1994. https://doi.org/10.1111/jth.14578CrossRef

54.

Connors JM (2020) Levy JH COVID-19 and its implications for thrombosis and anticoagulation. Blood. https://doi.org/10.1182/blood.2020006000CrossRef

55.

Fogarty H, Townsend L, Cheallaigh CN, Bergin C, Martin-Loeches I, Browne P et al (2020) COVID-19 coagulopathy in caucasian patients. Br J Haematol. https://doi.org/10.1111/bjh.16749CrossRef

56.

Chang JC (2019) Acute respiratory distress syndrome as an organ phenotype of vascular microthrombotic disease: based on hemostatic theory and endothelial molecular pathogenesis. Clin Appl Thromb/Hemost 25:1–20. https://doi.org/10.1177/1076029619887437CrossRef

57.

Zhang H, Penninger JM, Li Y, Zhong N, Slutsky A (2020) Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med 46:586–590. https://doi.org/10.1007/s00134-020-05985-9CrossRef

58.

Gheblawi M, Wang K, Viveiros A, Nguyen Q, Zhong JC, Turner AJ, Raizada MK, Grant MB, Oudit GY (2020) Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2. Circ Res 126:1456–1474. https://doi.org/10.1161/CIRCRESAHA.120.317015CrossRef

59.

Henry BM, Vikse J, Benoit S, Favaloro EJ, Lippi G (2020) Hyperinflammation and derangement of renin-angiotensin-aldosterone system in COVID-19: a novel hypothesis for clinically suspected hypercoagulopathy and microvascular immunothrombosis. Clin Chim Acta 26(507):167–173. https://doi.org/10.1016/j.cca.2020.04.027CrossRef

60.

Albini A, Di Guardo G, McClain Noonan D, Lombardo M (2020) The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor- and angiotensin II receptor blocker-based cardiovascular therapies. Intern Emerg Med 19:1–8. https://doi.org/10.1007/s11739-020-02364-6CrossRef

61.

Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, Mehra MR, Schuepbach RA, Ruschitzka F (2020) Moch endothelial cell infection and endotheliitis in COVID-19. Lancet 395:1417–1418. https://doi.org/10.1016/S0140-6736(20)30937-5CrossRef

62.

Levi M, Scully M, Singer M (2018) The role of ADAMTS-13 in the coagulopathy of sepsis. J Thromb Haemost 16:646–651. https://doi.org/10.1111/jth.13953CrossRef

63.

Bazzan M, Montaruli B, Sciascia S et al (2020) Low ADAMTS 13 plasma levels are predictors of mortality in COVID-19 patients. Intern Emerg Med. https://doi.org/10.1007/s11739-020-02394-0CrossRef

64.

Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W et al (2020) Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med. https://doi.org/10.1056/NEJMc2007575CrossRef

65.

Harzallah I, Debliquis A, Drénou B (2020) Lupus anticoagulant is frequent in patients with Covid-19. J Thromb Haemost. https://doi.org/10.1111/jth.14867CrossRef

66.

Bowles L, Platton S, Yartey N, Dave M, Lee K, Hart DP, MacDonald V, Green L, Sivapalaratnam S, Pasi KJ, MacCallum P (2020) Lupus anticoagulant and abnormal coagulation tests in patients with Covid-19. N Engl J Med. https://doi.org/10.1056/NEJMc2013656CrossRef

67.

Devreese KMJ (2014) Antiphospholipid antibody testing and standardization. Int J Lab Hematol 36:352–363. https://doi.org/10.1111/ijlh.12234CrossRef

68.

Devreese KMJ, Ortel TL, Pengo V, de Laat B (2018) Subcommittee on lupus anticoagulant/antiphospholipid antibodies. Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH. J Thromb Haemost 16:809–813. https://doi.org/10.1111/jth.13976CrossRef

69.

Abdel-Wahab N, Talathi S, Lopez-Olivo MA, Suarez-Almazor ME (2018) Risk of developing antiphospholipid antibodies following viral infection: a systematic review and meta-analysis. Lupus 27:572–583. https://doi.org/10.1177/0961203317731532CrossRef

70.

Galeano-Valle F, Oblitas CM, Ferreiro-Mazón MM, Alonso-Muñoz J, Del Toro-Cervera J, Demelo-Rodríguez P (2020) Antiphospholipid antibodies are not elevated in patients with severe COVID-19 pneumonia and venous thromboembolism. Thromb Res 192:113–115. https://doi.org/10.1016/j.thromres.2020.05.017CrossRef

71.

Li X, Ma X (2017) The role of heparin in sepsis: much more than just an anticoagulant. Br J Haematol 179:389–398. https://doi.org/10.1111/bjh.14885CrossRef

72.

Thachil J (2020) The versatile heparin in COVID-19. J Thromb Haemost 18:1020–1022. https://doi.org/10.1111/jth.14821CrossRef

73.

Huang X, Han S, Liu X, Wang T, Xu H, Xia B et al (2020) Both UFH and NAH alleviate shedding of endothelial glycocalyx and coagulopathy in LPS-induced sepsis. Exp Ther Med 19:913–922. https://doi.org/10.3892/etm.2019.8285CrossRef

74.

Milewska A, Zarebski M, Nowak P, Stozek K, Potempa J, Pyrc K (2014) Human coronavirus NL63 utilizes heparan sulfate proteoglycans for attachment to target cells. J Virol 88:13221–13230. https://doi.org/10.1128/JVI.02078-14CrossRef

75.

Marongiu F, Grandone E, Barcellona D (2020) Pulmonary thrombosis in 2019-nCoV pneumonia? J Thromb Haemost 18:1511–1513. https://doi.org/10.1111/jth.14818CrossRef

76.

Keshari RS, Silasi R, Popescu NI, Georgescu C, Chaaban H, Lupu C et al (2020) Fondaparinux pentasaccharide reduces sepsis coagulopathy and promotes survival in the baboon model of Escherichia coli sepsis. J Thromb Haemost 18:180–190. https://doi.org/10.1111/jth.14642CrossRef

77.

Xie Q, Spear JM, Noble AJ, Sousa DR, Meyer NL, Davulcu O et al (2017) The 2.8 Å Electron Microscopy Structure of Adeno-Associated Virus-DJ Bound by a Heparinoid Pentasaccharide. Mol Ther Methods Clin Dev. 5:1–12. https://doi.org/10.1016/j.omtm.2017.02.004CrossRef

78.

Liu X, Zhang X, Xiao Y, Gao T, Wang G, Wang Z et al (2020) Heparin-induced thrombocytopenia is associated with a high risk of mortality in critical COVID-19 patients receiving heparin-involved treatment. MedRxiv. https://doi.org/10.1101/2020.04.23.20076851CrossRef

79.

Landi A, De Servi S (2020) The burden of thrombotic complications in critically ill patients with COVID-19: charting the uncharted. Intern Emerg Med. https://doi.org/10.1007/s11739-020-02393-1CrossRef

Titel: COVID-19, coagulopathy and venous thromboembolism: more questions than answers
verfasst von: Marco Marietta
Valeria Coluccio
Mario Luppi
Publikationsdatum: 11.07.2020
Verlag: Springer International Publishing
Schlagwort: COVID-19
Erschienen in: Internal and Emergency Medicine / Ausgabe 8/2020
Print ISSN: 1828-0447
Elektronische ISSN: 1970-9366
DOI: https://doi.org/10.1007/s11739-020-02432-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

COVID-19, coagulopathy and venous thromboembolism: more questions than answers

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2020

The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor- and angiotensin II receptor blocker-based cardiovascular therapies: comment

Derivation and validation of the clinical prediction model for COVID-19

Characteristics and outcomes of Behçet’s syndrome patients with Coronavirus Disease 2019: a case series of 10 patients

Medical professionalism in times of COVID-19 pandemic: is economic logic trumping medical ethics?

COVID-19: in the uncertainty, do not try this at home

From the quarantine diary of an emergency physician: the coronavirus and the dysautonomic storm

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin